Alterations of glycaemia, insulin resistance and body mass index within the C-peptide optimal range in non-diabetic patients.
Body mass index
C-peptide
Glucose
Insulin resistance
Journal
Journal of applied biomedicine
ISSN: 1214-0287
Titre abrégé: J Appl Biomed
Pays: Poland
ID NLM: 101221755
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
17
07
2020
accepted:
28
11
2020
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
11
5
2022
Statut:
ppublish
Résumé
The study focused on changes or cut-offs of glycaemia, insulin resistance and body mass index within the C-peptide reference range (260-1730 pmol/l). The metabolic profile of individuals in the Czech Republic without diabetes (n = 3186) was classified by whiskers and quartiles of C-peptide into four groups with the following ranges: 290-510 (n = 694), 511-710 (n = 780), 711-950 (n = 720) and 951-1560 pmol/l (n = 673). Fasting levels of glucose, insulin, HOMA IR (Homeostasis Model Assessment for Insulin Resistance) and BMI (body mass index) were compared by a relevant C-peptide range. Participants taking medication to control glycaemia were excluded. The evaluation involved correlations between C-peptides and the above parameters, F-test and t-test. Changes in glucose levels (from 5.3 to 5.6 mmol/l) between the groups were lower in comparison to insulin, which reached relatively greater changes (from 4.0 to 14.2 mIU/l). HOMA IR increased considerably with growing C-peptide concentrations (0.9, 1.5, 2.2 and 3.5) and BMI values showed a similar trend (28.3, 31.0, 33.6 and 37.4). Considerable changes were observed for insulin (5.2 mIU/l, 57.8%) and HOMA IR (1.3, 61.3%) between groups with C-peptide ranges of 711-950 and 951-1560 pmol/l. Although correlations involving C-peptide, insulin, glucose and BMI seemed to be non-significant (up to rxy = 0.25), the mean values of insulin, HOMA IR and BMI showed statistically significant changes between all groups with various C-peptide concentrations (p ≤ 0.001). Generally, most important differences appeared in glucose metabolism and body mass index between C-peptide ranges of 711-950 and 951-1560 pmol/l. Absolute and relative changes of C-peptide concentrations are possible to use for the assessment of glucose regulatory mechanism. The spectrum of investigated parameters could be a useful tool to prevent the risks linked with the alterations of glycaemia.
Identifiants
pubmed: 34907766
doi: 10.32725/jab.2020.018
doi:
Substances chimiques
Blood Glucose
0
C-Peptide
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136-142Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Andrade RLM, Gigante DP, de Oliveira IO, Horta BL (2018). C-peptide and cardiovascular risk factors among young adults in a southern Brazilian Cohort. BMC Endocr Disord 18: 80. DOI: 10.1186/s12902-018-0308-5.
pubmed: 30400868
doi: 10.1186/s12902-018-0308-5
Bilal A, Basanagouda SP, Thaseen A (2010). Significance of C-peptide in type 2 diabetics - a study in the North Karnataka population of India. Al Ameen J Med Sci. 3: 65-78.
Buse JB, Polonsky KS, Burant CF (2008). Type 2 diabetes mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Williams Textbook of Endocrinology. Elsevier Saunders, Philadelphia, pp. 1329-1391.
C-peptide serum analyze (2020). Manual of recommendations of IKEM. [online] [cit. 2020-07-15]. Available at: https://www2.ikem.cz/plm_lp/_LP_05206-L0000006.htm
Cardellini M, Farcomeni A, Ballanti M, Morelli M, Davato F, Cardolini I, et al. (2017). C-peptide: a predictor of cardiovascular mortality in subjects with established atherosclerotic disease. Diabetes Vasc Dis Res 14: 395-399. DOI: 10.1177/1479164117710446.
pubmed: 28565926
doi: 10.1177/1479164117710446
Christensen MB, Gaede P, Hommelc E, Gotfredsen A, Nørgaard K (2019). Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. Diabetes Metab. 46: 61-65. DOI: 10.1016/j.diabet.2019.02.002.
pubmed: 30796973
doi: 10.1016/j.diabet.2019.02.002
Francis S, Padinjareveedu SC, Nesheera KK, Jacob J (2017). Fasting C-peptide correlated with fasting insulin and post glucose load C-peptides in young adults but the C-peptides could not be partitioned into groups with and without family history of type 2 diabetes mellitus. Int J Contemp Med Res 4: 467-472.
Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Gil MJ, et al. (2011). Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity (Silver Spring) 19: 1439-44. DOI: 10.1038/oby.2011.36.
pubmed: 21394093
doi: 10.1038/oby.2011.36
Haban P, Simoncic R, Zidekova E, Ozdin L (2002). Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X- syndrome. Med Sci Monit 8: 175-179.
Horáková D, Štěpánek L, Janout V, Janoutová J, Pastucha D, Kollárová H, et al. (2019). Optimal homeostasis model assessment of insulin resistance (HOMA-IR) cut off in Czech population. Medicina 55: 158. DOI: 10.3390/medicina55050158.
pubmed: 31108989
doi: 10.3390/medicina55050158
Juszczak A, Pryse R, Schuman A, R Owen K (2016). When to consider a diagnosis of MODY at the presentation of diabetes. Br J Gen Pract 66: 457-459. DOI: 10.3399/bjgp16X685537.
pubmed: 27231307
doi: 10.3399/bjgp16X685537
Khan HA, Sobki SH, Ekhzaimy A, Khan I, Almusawi MA (2018). Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals. Saudi J Bio Sci 27: 1729-1732. DOI: 10.1016/j.sjbs.2018.05.027.
pubmed: 30591792
doi: 10.1016/j.sjbs.2018.05.027
Li Y, Meng L, Zheng L (2015). Association between serum C-peptide as a risk factor for cardiovascular disease and high-density lipoprotein cholesterol levels in nondiabetic individuals. PLoSOne 10: e112281. DOI: 10.1371/journal.pone.0112281.
pubmed: 25559358
doi: 10.1371/journal.pone.0112281
Methodology of glucose, total, HDL and LDL cholesterol (2020). Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové. [online] [cit. 2020-07-15]. Available at: http://ukbd.fnhk.cz/seznam-metod.html
Pagana K, Pagana TJ (2013). Mosby's Manual of Diagnostic and Laboratory Tests. 5th ed. Elsevier Saunders, St. Louis.
Palmer, JP (2009). C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 25: 325-328. DOI: 10.1002/dmrr.943.
pubmed: 19267337
doi: 10.1002/dmrr.943
Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR (2016). Correlation among hypoglycemia, glycemic variability, and C-peptide preservation after alefacept therapy in patients with type 1 diabetes mellitus: Analysis of data from the immune tolerance network T1 DAL trial. Clin Ther 38: 1327-1339. DOI: 10.1016/j.clinthera.2016.04.032.
pubmed: 27209482
doi: 10.1016/j.clinthera.2016.04.032
Pujia A, Gazzaruso C, Montalcini T (2017). An update on the potential role of C-peptide in diabetes and osteoporosis. Endocrine 58: 408-12. DOI: 10.1007/s12020-017-1286-5.
pubmed: 28374151
doi: 10.1007/s12020-017-1286-5
S-C-peptide analyze (2020). Manual of recommendations of DPC. Biolab company. [online] [cit. 2020-07-15]. Available at: https://www.biolab-kt.cz/laboratorni-prirucka/HVEZDAAAWX.htm
Shetty V, Jain HR, Singh G, Parekh S, Shetty S (2017). C-peptide levels in diagnosis of diabetes mellitus: a case-control study. Int J Sci Stud 4: 7-13. DOI: 10.17354/ijss/2017/38.
doi: 10.17354/ijss/2017/38
Siy YP, Dampil OAC, Quimpo AJ (2017). The correlation of body mass index with fasting C-peptide levels of newly diagnosed type 2 diabetes mellitus Filipino patients. Philipp J Intern Med 55: 1-5.
Smith JD, Wijeratne N, McNeil A (2019). The need to feed? Is blood glucose above 8 mmol/L needed for the correct interpretation of C-peptide in patients with diabetes? Pathology 51: 114. DOI: 10.1016/j.pathol.2018.12.321.
doi: 10.1016/j.pathol.2018.12.321
Svačina Š, Bretšnajdrová A (2003). Diabetes and obesity, 1st ed. Prague: Maxdorf.
Test ID: CPR, C-Peptide serum (2020). Manual of Mayo Clinic Laboratories. [online] [cit. 2020-07-15]. Available at: https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/8804
Thunander M, Törn C, Petersson Ch, Ossiansson B, Fornande J, Landin-Olsson M (2012). Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetesin Kronoberg, Sweden. Eur J Endocrinol 166: 1021-1029. DOI: 10.1530/EJE-11-0797.
pubmed: 22436402
doi: 10.1530/EJE-11-0797
Toffolo G, De Grandi F, Cobelli C (1995). Estimation of beta-cell sensitivity from intravenous glucose tolerance test C-peptide data. Knowledge of the kinetics avoids errors in modeling the secretion. Diabetes 44: 845-854. DOI: 10.2337/diab.44.7.845.
pubmed: 7789653
doi: 10.2337/diab.44.7.845
Wahren J (2004). C-peptide: new findings and therapeutic implications in diabetes Clin Physiol Funct Imaging 24: 180-189. DOI: 10.1111/j.1475-097X.2004.00558.x.
pubmed: 15233831
doi: 10.1111/j.1475-097X.2004.00558.x
Wang Y, Wan H, Chen Y, Xia F, Zhang W, Wang C, et al. (2019). Association of C-peptide with diabetic vascular complications in type 2 diabetes. Diabetes Metab 46: 33-40. DOI: 10.1016/j.diabet.2019.04.004.
pubmed: 31026551
doi: 10.1016/j.diabet.2019.04.004
Yosten GL, Maric-Bilkan C, Luppi P, Wahren J (2014). Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab 307: 955-968. DOI: 10.1152/ajpendo.00130.2014.
pubmed: 25249503
doi: 10.1152/ajpendo.00130.2014
Zierath JR, Handberg A, Tally M, Wallberg-Henriksson H (1996). C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation. Diabetologia 39: 306-313. DOI: 10.1007/BF00418346.
pubmed: 8721776
doi: 10.1007/BF00418346